XML 74 R57.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Segment Data - Operating Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Mar. 31, 2022
Revenues $ 54,287 $ 54,696 $ 163,489 $ 125,456  
Total revenues 54,287 54,696 163,489 125,456  
Gross profit (loss) 32,765 28,627 100,492 73,978  
Gross profit (loss) 32,765 28,627 100,492 73,978  
Operating expenses 29,363 31,139 97,689 69,166  
Operating income (loss) 3,402 (2,512) 2,803 4,812  
Nonoperating expense (income), net 1,486 (171) 2,915 1,192  
Earnings (loss) before income taxes 1,916 (2,341) (112) 3,620  
Total inventories 33,739   33,739   $ 24,606
Operating Segments [Member]          
Revenues [1] 54,287 54,696 163,489 125,456  
Total revenues [1] 54,287 54,696 163,489 125,456  
Gross profit (loss) 32,758 28,727 100,520 74,174  
Gross profit (loss) 32,758 28,727 100,520 74,174  
Operating expenses 29,363 31,139 97,689 69,166  
Operating income (loss) 3,402 (2,512) 2,803 4,812  
Nonoperating expense (income), net 1,486 (171) 2,915 1,192  
Operating Segments [Member] | Clinical Genomics [Member]          
Revenues 15,585 16,485 48,525 16,485  
Total revenues 15,585 16,485 48,525 16,485  
Gross profit (loss) 8,045 3,924 26,535 3,924  
Gross profit (loss) 8,045 3,924 26,535 3,924  
Total inventories 14,591   14,591   11,802
Operating Segments [Member] | Sterilization and Disinfection Control [Member]          
Revenues 16,283 13,831 48,021 43,014  
Total revenues 16,283 13,831 48,021 43,014  
Gross profit (loss) 11,614 9,945 34,581 31,859  
Gross profit (loss) 11,614 9,945 34,581 31,859  
Total inventories 3,022   3,022   2,176
Operating Segments [Member] | Biopharmaceutical Development [Member]          
Revenues 11,646 12,756 34,757 32,188  
Total revenues 11,646 12,756 34,757 32,188  
Gross profit (loss) 7,359 8,768 21,993 20,061  
Gross profit (loss) 7,359 8,768 21,993 20,061  
Total inventories 7,797   7,797   4,495
Operating Segments [Member] | Calibration Solutions [Member]          
Revenues [2] 10,773 11,624 32,186 33,769  
Total revenues [2] 10,773 11,624 32,186 33,769  
Gross profit (loss) 5,740 6,090 17,411 18,330  
Gross profit (loss) 5,740 6,090 17,411 18,330  
Total inventories 8,329   8,329   $ 6,133
Corporate, Non-Segment [Member]          
Gross profit (loss) [3] 7 (100) (28) (196)  
Gross profit (loss) [3] $ 7 $ (100) $ (28) $ (196)  
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals
[2] Revenues in the Clinical Genomics division represent transactions subsequent to the Agena Acquisition on October 20, 2021.
[3] Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other.